MetaADEDB 2.0 @ LMMD
Hydron;3-phenyldiazenylpyridine-2,6-diamine;chloride
(QQBPIHBUCMDKFG-UHFFFAOYSA-N)
Structure
SMILES
Nc1ccc(c(n1)N)N=Nc1ccccc1.Cl
Molecular Formula:
C11H12ClN5
Molecular Weight:
249.699
Log P:
4.6258
Hydrogen Bond Acceptor:
5
Hydrogen Bond Donor:
3
TPSA:
89.65
CAS Number(s):
136-40-3
Synonym(s)
1.
Hydron;3-phenyldiazenylpyridine-2,6-diamine;chloride
2.
Phenazopyridine hydrochloride
External Link(s)
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1CyanosisFAERS: 4US FAERS
2Renal tubular necrosisFAERS: 4US FAERS
3Suicide attemptFAERS: 4US FAERS
4Abdominal PainFAERS: 3US FAERS
5ChromaturiaFAERS: 3
Canada Vigilance: 2
Canada Vigilance
US FAERS
6Accidental drug intake by childFAERS: 2US FAERS
7Drug toxicityFAERS: 2US FAERS
8FatigueFAERS: 2US FAERS
9LethargyFAERS: 2US FAERS
10Medication ErrorFAERS: 2
Canada Vigilance: 1
Canada Vigilance
US FAERS
11OverdoseFAERS: 2US FAERS
12Peritoneal DialysisFAERS: 2US FAERS
13jaundiceFAERS: 2
Canada Vigilance: 3
Canada Vigilance
SIDER
US FAERS
14Accidental exposureFAERS: 1US FAERS
15Alanine Aminotransferase IncreasedFAERS: 1US FAERS
16AlbuminuriaFAERS: 1US FAERS
17Blood sodium decreasedFAERS: 1US FAERS
18Culture urine positiveFAERS: 1US FAERS
19Drug screen positiveFAERS: 1US FAERS
20ErythemaFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
21HepatomegalyFAERS: 1US FAERS
22HypoventilationFAERS: 1US FAERS
23IsosthenuriaFAERS: 1US FAERS
24Livedo ReticularisFAERS: 1US FAERS
25Neutrophil percentage increasedFAERS: 1US FAERS
26NocturiaFAERS: 1US FAERS
27Occult blood positiveFAERS: 1US FAERS
28Ocular icterusFAERS: 1US FAERS
29PallorFAERS: 1US FAERS
30PoisoningFAERS: 1US FAERS
31PruritusFAERS: 1
Canada Vigilance: 5
Canada Vigilance
SIDER
US FAERS
32RhabdomyolysisFAERS: 1US FAERS
33SomnolenceFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
34Urinary IncontinenceFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
35WheezingFAERS: 1US FAERS
36Acute kidney injuryCanada Vigilance: 1Canada Vigilance
37Blood urine presentCanada Vigilance: 1Canada Vigilance
38ChillsCanada Vigilance: 1Canada Vigilance
39DermatitisSIDER
40Drug ineffectiveCanada Vigilance: 1Canada Vigilance
41DyspepsiaSIDER
42DysuriaCanada Vigilance: 1Canada Vigilance
43HeadacheCanada Vigilance: 1Canada Vigilance
SIDER
44HepatitisSIDER
45HypersensitivitySIDER
46LeukocytosisCanada Vigilance: 1Canada Vigilance
47Metabolic acidosisCanada Vigilance: 1Canada Vigilance
48NauseaCanada Vigilance: 3Canada Vigilance
SIDER
49NephrolithiasisSIDER
50Rash erythematousCanada Vigilance: 2Canada Vigilance
51Skin UlcerCanada Vigilance: 1Canada Vigilance
52TachycardiaCanada Vigilance: 1Canada Vigilance
53TremorCanada Vigilance: 1Canada Vigilance
54UreterolithiasisCanada Vigilance: 1Canada Vigilance
55Visual ImpairmentSIDER
56Visual disturbanceSIDER
57VomitingCanada Vigilance: 5Canada Vigilance
SIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.